Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide for Severe COVID-19 in Cancer Patients
NCT04532372Phase 2Completed
- Sponsor
- City of Hope
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of leflunomide in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose at 28 days and Clinical Activity (Response) at 28 days. Started Jan 2021; status: completed.
02
Drugs
leflunomide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04532372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532372.